World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
37429
World Ranking
11166
National Ranking
449

Geoffrey Liu publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Geoffrey Liu sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 837 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Geoffrey Liu D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Geoffrey Liu sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Geoffrey Liu is affiliated with the Princess Margaret Cancer Centre in Canada with a research focus centered on Medicine, particularly within Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research, and Surgery. Their work extensively covers topics related to lung cancer treatments, research studies, diagnosis, and treatment, along with cancer genomics, diagnostics, immunotherapy, and biomarkers, as well as studies on head and neck cancer and the application of radiomics and machine learning in medical imaging.

The scientist has contributed frequently to high-impact journals, with significant numbers of publications in the following venues:

  • Journal of Clinical Oncology (65 publications)
  • Journal of Thoracic Oncology (37 publications)
  • Annals of Oncology (31 publications)
  • Lung Cancer (29 publications)
  • Cancer Research (27 publications)

Geoffrey Liu's recent papers include notable works such as:

  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer (2020), New England Journal of Medicine
  • Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study (2024), Journal of Clinical Oncology
  • Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study (2022), The Lancet Respiratory Medicine
  • Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy (2021), Journal of Thoracic Oncology
  • Causal relationships between body mass index, smoking and lung cancer: Univariable and multivariable Mendelian randomization (2020), International Journal of Cancer

The scientist has collaborated frequently with several coauthors, including:

  • Natasha B. Leighl (102 collaborations)
  • Frances A. Shepherd (97 collaborations)
  • Adrian G. Sacher (85 collaborations)
  • Ming-Sound Tsao (82 collaborations)
  • Rayjean J. Hung (75 collaborations)

Geoffrey Liu's research areas span highly specialized subjects within lung cancer and cancer biology, highlighting an extensive focus on advanced lung cancer treatments and the molecular mechanisms underlying cancer persistence and resistance. Their research output and collaboration network reflect sustained contributions to these critical areas of clinical and translational cancer research.

Best Publications

  • Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan

  • A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25

    Rayjean J. Hung;James D. Mckay;Valerie Gaborieau;Paolo Boffetta

  • Patient preferences for oral versus intravenous palliative chemotherapy.

    G Liu;E Franssen;M I Fitch;E Warner

  • Probability of Cancer in Pulmonary Nodules Detected on First Screening CT

    Annette McWilliams;Martin C. Tammemagi;John R. Mayo;Heidi Roberts

  • Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes

    James D McKay;Rayjean J Hung;Younghun Han;Xuchen Zong

  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Todd M. Bauer;Filippo de Marinis;Enriqueta Felip

  • Sensitive tumour detection and classification using plasma cell-free DNA methylomes

    Shu Yi Shen;Rajat Singhania;Gordon Fehringer;Ankur Chakravarthy

  • Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study

    Robert Carreras-Torres;Mattias Johansson;Philip C. Haycock;Kaitlin H. Wade

  • Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

    Alice T Shaw;Tae Min Kim;Lucio Crinò;Cesare Gridelli

  • Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

    Dong Wan Kim;Ranee Mehra;Daniel S W Tan;Enriqueta Felip

  • Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer

    Yufei Wang;James D McKay;Thorunn Rafnar;Zhaoming Wang

  • XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non—Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy

    Sarada Gurubhagavatula;Geoffrey Liu;Sohee Park;Wei Zhou

  • Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

    Wei Zhou;Sarada Gurubhagavatula;Geoffrey Liu;Sohee Park

  • Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

    Erin L. Stewart;Samuel Zhixing Tan;Geoffrey Liu;Ming-Sound Tsao

  • Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.

    Geeta Lal;Geoffrey Liu;Beverley Schmocker;Pardeep Kaurah

  • Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma

    Harvey I. Pass;Stephen M. Levin;Michael R. Harbut;Jonathan Melamed

  • Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors

    John T;Liu G;Tsao Ms

  • Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk

    Wei Zhou;Geoffrey Liu;David P Miller;Sally W Thurston

  • Circulating 25-Hydroxyvitamin D Levels Predict Survival in Early-Stage Non-Small-Cell Lung Cancer Patients

    Wei Zhou;Rebecca S. Heist;Geoffrey Liu;Kofi Asomaning

  • Previous Lung Diseases and Lung Cancer Risk: A Pooled Analysis From the International Lung Cancer Consortium

    Darren R. Brenner;Paolo Boffetta;Eric J. Duell;Heike Bickeböller

Frequent Co-Authors

Wei Xu
Wei Xu Shenzhen University
David C. Christiani
David C. Christiani Harvard University
Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre
Natasha B. Leighl
Natasha B. Leighl Princess Margaret Cancer Centre
Ming-Sound Tsao
Ming-Sound Tsao Princess Margaret Cancer Centre
Rayjean J. Hung
Rayjean J. Hung Lunenfeld-Tanenbaum Research Institute
John C. Wain
John C. Wain Harvard University
Stig E. Bojesen
Stig E. Bojesen University of Copenhagen
Christopher I. Amos
Christopher I. Amos Baylor College of Medicine
Thomas J. Lynch
Thomas J. Lynch Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in medicine but want flexible study options, there are several online programs that support various healthcare career paths. For registered nurses seeking career advancement, asn to fnp programs offer a bridge to become Family Nurse Practitioners, helping you move into advanced practice roles with a graduate degree.

Nutrition is a rapidly growing field, and those passionate about food science and wellness can explore the best online nutrition programs to launch or advance their careers. These programs cover essential topics like dietetics, human biology, and public health, and offer plenty of distance learning options.

Aspiring healthcare administrators should consider cahme accredited mha online programs, which are respected for their rigorous standards and prepare graduates for high-level leadership roles in hospitals, clinics, and other organizations.

Finally, registered nurses looking to build on their education might wonder, does rn to bsn require clinicals? Some online RN to BSN programs are designed to be completed without in-person clinicals, making them even more accessible for working professionals.

Best Scientists Citing Geoffrey Liu

Trending Scientists